5-5-Membered fused heterocyclic compound and use thereof as HCV polymerase inhibitor
申请人:Mizojiri Ryo
公开号:US20090036444A1
公开(公告)日:2009-02-05
The present invention relates to a fused ring compound represented by the following formula [I]
wherein each symbol is as defined in the specification, or a pharmaceutically acceptable a salt thereof, and a hepatitis C virus (HCV) polymerase inhibitor and a therapeutic agent for hepatitis C containing this compound. The compound of the present invention shows an anti-HCV activity based on the HCV polymerase inhibitory activity, and useful as an agent for the prophylaxis or treatment of hepatitis C.
本发明涉及一种由以下式[I]表示的融合环化合物,其中每个符号如规范中所定义,或其药学上可接受的盐,以及一种丙型肝炎病毒(HCV)聚合酶抑制剂和治疗丙型肝炎的药物,本发明的化合物基于HCV聚合酶抑制活性具有抗HCV活性,是一种预防或治疗丙型肝炎的药剂。